PhD position in cancer research

Working Environment

You will join a collaborative national network of leading Dutch universities and medical centers. Across the consortium, researchers apply cutting-edge omics platforms, mechanistic modelling, molecular biology, and advanced radiation technologies to answer key questions in radiation onco-immunology. More information on the participating researchers and their research interests can be found at their institute locations.
- Prof. M. van Vugt (PhD1); Dr. L. Barazzuol and Prof. R. Coppes (PhD5), UMCG;
- Prof. M. Vooijs and Prof. K. Rouschop (PhD2), Maastricht University;
- Prof. G. Adema and Dr. M. Ansems (PhD3), Radboudumc;
- Dr. D. van Gent and Dr. J. Essers (PhD4), Erasmus MC.

Job description

IMMUNO-PROT is a national, multidisciplinary research consortium funded by the Dutch Cancer Society (KWF) and coordinated by the University Medical Center Groningen (UMCG), uniting the three national proton therapy centers (UMCG PTC, HollandPTC, Maastro/ZonPTC) with Radboudumc’s onco-radiation immunology expertise.
This project aims to establish the scientific foundation required to optimize proton therapy-immunotherapy combination strategies for head-and-neck cancer. By elucidating the mechanisms that drive radiation-induced immunogenic responses, we seek to inform and accelerate future clinical translation. Our central hypothesis is that proton therapy enhances the efficacy of immunotherapy by eliciting distinct tumour-directed immune responses while preserving systemic immune competence.
The consortium includes five full time 4-year long PhD positions across the Netherlands, offering training, cutting-edge research and interdisciplinary collaboration in molecular, radiation and immune oncology. Below an overview of the work-packages (WPs) and the PhD project topics.
Available PhD positions
WP1: Proton therapy-induced cell-intrinsic inflammatory signalling
PhD1: This PhD project will dissect the molecular mechanisms involving DNA repair, cell cycle control and inflammatory signalling triggered by proton therapy. We will identify underlying mechanisms and aim to reveal vulnerabilities that are therapeutically actionable to potentiate proton therapy (UMCG, Groningen, The Netherlands).
PhD2: This PhD project aims to identify actionable mediators of proton-induced secreted inflammatory responses, including soluble factors and extracellular vesicles, that can enhance anti-tumour immunity using cell models and patient-derived head-and-neck cancer organoids, and to define corresponding patient-cohort biomarkers to guide proton therapy-immunotherapy combinations (Maastricht University, Maastricht, The Netherlands).
WP2: Immune impact and combined responses of proton therapy with immunomodulatory agents
PhD3: This PhD project aims to define how radiotherapy and proton therapy modulate immune responses, both alone and in combination with immunomodulatory agents. Molecular and immunological effects on immune cell function and immune-tumour cell crosstalk will be examined in 2D/3D head-and-neck cancer co-cultures and ex vivo tissue slice models, in collaboration with Erasmus MC, using state-of-the-art technologies (Radboudumc, Nijmegen, The Netherlands).
WP3: Optimal proton therapy and immunotherapy in vivo combination strategies
PhD4: This PhD project will investigate interactions between immune cells and tumour cells using patient-derived head-and-neck cancer slice cultures and in vivo models, including the analysis of proton-induced immunomodulatory effects and sparing of lymphoid structures. Detailed immune profiling will be performed in close collaboration with Radboudumc (Erasmus MC, Rotterdam, The Netherlands).
PhD5: Using patient-derived head-and-neck cancer tumoroids, salivary gland organoids, and in vivo models, this project focuses on validating recently identified immunomodulatory targets, such as inflammatory-response agonists, as well as novel targets, in combination with proton therapy and ultra-high-dose-rate (FLASH) proton therapy (UMCG, Groningen, The Netherlands).

Requirements

- Master's degree in a relevant biomedical field, allowing enrolment in a PhD program at the hiring institute
- Experience in molecular cell biology, radiation biology, immunology and/or bioinformatics; affinity with head-and-neck cancer research is an advantage
- Strong motivation to conduct experimental, lab-based oncology research
- Excellent communication skills and ability to work effectively within a team
Students completing their Master’s degree during the application period are welcome to apply.

Conditions of employment

- Enrolment in the PhD program of the hosting institution
- A stimulating, interdisciplinary research environment
- Opportunities for training, conferences, and national collaborations across the consortium
- A preferred start date of July 1, 2026 (flexible).
Employment conditions according to the regulations of each participating institute:
UMCG, Radboudumc, and Erasmus MC (PhD1, PhD3, PhD 4, PhD5): Your salary will be € 3,109 gross per month in the first year and up to a maximum of € 3.939,- gross per month in the last fourth year (scale PhD of 1st of July 2025). Additionally, the UMCG offers an 8% holiday allowance, an 8.3% year-end bonus.The conditions of employment comply with the Collective Labour Agreement for Medical Centres (CAO-UMC). The duration of the project is 48 months. The initial contract will be for 1 year and after positive evaluation this will be extended for 3 additional years.
Maastricht University (PhD2): Your salary will be € 3,059 gross per month in the first year and up to a maximum of € 3.881,- gross per month in the last fourth year (scale PhD of 1st of July 2025). In addition, the Maastricht University will offer you 8% holiday pay and an 8.3% end-of-year bonus. The terms of employment comply with the Collective Labour Agreement of Dutch Universities (CAO Nederlandse Universiteiten). The duration of the project is 48 months. The initial contract will be for 1 year and after positive evaluation this will be extended for 3 additional years.
For questions about the positions
For more information about the PhD positions please contact:
- Dr. L. Barazzuol, Consortium leader, email: [email protected];
- Prof. M. van Vugt, email: [email protected];
- Prof. M. Voijs, email: [email protected];
- Prof. G. Adema, email: [email protected];
- Dr. D. van Gent, email: [email protected];
- Dr. J. Essers, email: [email protected];
Application instructions
Please submit your application using the digital application form at the bottom of this page. Only applications submitted through the digital form will be considered.
Your application should include:
- A short motivation letter (you may indicate up to two preferred PhD positions; in case of interest in multiple positions, a single application suffices).
- A copy of your CV.
- The names and contact information of two references.
Links
Moleculair radiotion biology
Van Vugt lab dna damage response in cancer
Effects of radiation on normal tissues
Marc Vooijs lab
Research groups molecular immunology
Dik van Gent
Jeroen Essers

Additional information

Please use the the digital application form at the bottom of this page - only these will be processed. You can apply until 1 April 2026. Within half an hour after sending the digital application form you will receive an email- confirmation with further information.
Digital application form